NasdaqGM:LRMR
NasdaqGM:LRMRBiotechs

Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?

Larimar Therapeutics recently announced positive data from its long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in patients with Friedreich's Ataxia, alongside an update on its development program. This milestone highlights progress in advancing novel treatments for a rare neurological disease, capturing interest among rare disease and biotech stakeholders. We’ll explore how the encouraging clinical results for nomlabofusp are influencing Larimar...
LSE:GRG
LSE:GRGHospitality

Has Greggs Recent Share Price Recovery Changed the Outlook for 2025?

Thinking about what to do with Greggs shares? You are not alone, especially as the bakery giant's stock has shown a bit of both sizzle and slump this year. If you have been watching the chart, you probably noticed the share price climbed 5.0% in just the past week and 4.8% over the last month, hinting at renewed optimism or perhaps a shift in how investors are weighing up Greggs's future potential. However, zooming out, it is clear this has been a tough year with the stock still down over 40%...
ASX:VEE
ASX:VEEMachinery

Why VEEM (ASX:VEE) Is Up 7.9% After Securing a US Navy Supply Deal With Northrop Grumman

VEEM Limited recently announced a nine-year manufacturing licence agreement with Northrop Grumman, valued initially at up to US$33 million, to supply precision components for the US Navy's Virginia Class submarine program, and completed a A$14 million capital raise to support its growing defence sector operations. This move marks VEEM's entry into critical US defence supply chains and follows new accreditations with top-tier naval contractors, highlighting the company's expanding global...
TSX:AYA
TSX:AYAMetals and Mining

Assessing Aya Gold & Silver After Shares Surge 15% on Bullish Silver Market Trends

If you’re following Aya Gold & Silver, chances are you’re asking yourself whether now is the moment to buy, hold, or wait. The stock’s recent moves have been hard to ignore. In just the past week, Aya is up by nearly 15%, capping off a 30-day jump of over 15% and an eye-popping year-to-date return of almost 50%. The longer-term story is just as compelling, with gains over 90% in three years and more than 500% over five years. It’s no wonder investors can’t help but wonder if there’s more...